Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1982 Jan;37(1):57–60. doi: 10.1136/thx.37.1.57

Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma.

J W Millar, P Roscoe, S J Pearce, S Ludgate, N W Horne
PMCID: PMC459246  PMID: 7041323

Abstract

Ninety-two patients with histologically confirmed bronchogenic carcinoma treated by surgical resection of the tumour were subsequently given immunotherapy with BCG (Glaxo). The patients were randomly allocated into three groups. Twenty-nine patients received multipuncture BCG (50 to 250 X 10(6) viable units), and twenty-six patients intradermal BCG (0.4 to 0.9 X 10(6) viable units), treatment being given at 1, 2, 6, 9, 13, 26, and 52 weeks after operation. Thirty-seven control patients did not receive any BCG immunotherapy; two patients in the control group were lost to follow-up. The overall five-year survival in all groups was 37%. Favourable prognostic features were squamous carcinoma (45% five-year survival), the absence of involved mediastinal nodes at operation (46%), and lobectomy (45%), but even the presence of involved mediastinal nodes was associated with a 19% five-year survival. There were no statistically significant differences between the survival of the control group and either group treated by immunotherapy considered individually or in combination. The influence of the presence of positive mediastinal lymph nodes and the extent of surgical resection on survival was not affected by immunotherapy. No serious side-effects of immunotherapy were encountered.

Full text

PDF
57

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Pimm M. V. Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol. 1971 Nov;16(9):875–881. [PubMed] [Google Scholar]
  2. Barkas T., AL-Khateeb S. F., Irvine W. J., Davidson N. M., Roscoe P. Inhibition of antibody-dependent cell-mediated cytotoxicity (ADCC) as a means of detection of immune complexes in the sera of patients with thyroid disorders and bronchogenic carcinoma. Clin Exp Immunol. 1976 Aug;25(2):270–279. [PMC free article] [PubMed] [Google Scholar]
  3. Barnes E. W., Farmer A., Penhale W. J., Irvine W. J., Roscoe P., Horne N. W. Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer. 1975 Jul;36(1):187–193. doi: 10.1002/1097-0142(197507)36:1<187::aid-cncr2820360117>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  4. Edwards F. R. Use of BCG as an immunostimulant after resection of carcinoma of the lung: a two-year assessment of a trial of 500 patients. Thorax. 1979 Dec;34(6):801–806. doi: 10.1136/thx.34.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edwards F. R., Whitwell F. Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report. Thorax. 1978 Apr;33(2):250–252. doi: 10.1136/thx.33.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Grant R. M., Mackie R., Cochran A. J., Murray E. L., Hoyle D., Ross C. Results of administering B.C.G. to patients with melanoma. Lancet. 1974 Nov 9;2(7889):1096–1100. doi: 10.1016/s0140-6736(74)90867-8. [DOI] [PubMed] [Google Scholar]
  7. Hersh E. M., Gutterman J. U., Mavligit G. M. BCG as adjuvant immunotherapy for neoplasia. Annu Rev Med. 1977;28:489–515. doi: 10.1146/annurev.me.28.020177.002421. [DOI] [PubMed] [Google Scholar]
  8. Hersh E. M., Gutterman J. U., Mavligit G. M. Immunotherapy of leukemia. Med Clin North Am. 1976 Sep;60(5):1019–1042. doi: 10.1016/s0025-7125(16)31846-6. [DOI] [PubMed] [Google Scholar]
  9. Holmes E. C., Ramming K. P., Bein M. E., Coulson W. F., Callery C. D. Intralesional BCG immunotherapy of pulmonary tumors. J Thorac Cardiovasc Surg. 1979 Mar;77(3):362–368. [PubMed] [Google Scholar]
  10. Mathé G., Amiel J. L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J. R., Hayat M., De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
  11. McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
  12. Millar J. W., Hunter A. M., Wightman A. J., Horne N. W. Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma. Eur J Respir Dis. 1980 Jun;61(3):162–166. [PubMed] [Google Scholar]
  13. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  14. Zbar B., Rapp H. J., Ribi E. E. Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets. J Natl Cancer Inst. 1972 Mar;48(3):831–835. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES